Brawn Biotech Ltd (BRAWN) is currently trading at 22.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Brawn Biotech Limited is a listed Indian pharmaceutical wholesaler and distributor that trades in herbals, ayurvedic, critical care and broad pharmaceutical ranges, supplies government hospitals as a consignee agent, and holds product registrations across domestic and international markets while operating under the corporate brand Brawn Biotech. The Board approved and published unaudited financial results for the quarter and nine months ended 31 December 2025; the statutory auditor performed a limited review under SRE 2410 and issued an unmodified conclusion, while the CFO provided a certification confirming compliance and absence of material fraud or internal control changes. The company traces its origin to 1985 and repositioned as Brawn Biotech in 2010, operating as an integrated healthcare group with distribution and institutional supply focus; it emphasizes registrations with major health and government institutions and acts as consignee agent for government hospital supplies, a channel that materially influences sales visibility and customer mix. The publicly filed results and board minutes reveal limited disclosure on segmental or granular financial metrics in the available investor material; the presentation contains OCR noise and garbled tables, so precise numeric interpretation is unreliable without retrieving the original filing PDF or exchange filings for accurate figures.

Over the past 52 weeks, Brawn Biotech Ltd has traded between a low of ₹17.71 and a high of ₹26.64. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Brawn Biotech Ltd has a market capitalization of approximately 6.60. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Brawn Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 8.15 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 6.60 Cr, Brawn Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Brawn Biotech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Brawn Biotech Ltd is 8.15. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.